紫杉醇和顺铂同期放化疗治疗宫颈腺癌的长期疗效。
Long-term Outcomes of Cervical Adenocarcinoma Treated With Concurrent Chemoradiotherapy Using Paclitaxel and Cisplatin.
机构信息
Department of Obstetrics and Gynecology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Department of Radiology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
出版信息
In Vivo. 2020 Sep-Oct;34(5):2739-2743. doi: 10.21873/invivo.12096.
BACKGROUND/AIM: We retrospectively analyzed the locally advanced adenocarcinoma (AC)/adenosquamous carcinoma (ASC) of the uterine cervix treated with concurrent chemoradiotherapy using cisplatin plus paclitaxel (TP-CCRT).
PATIENTS AND METHODS
Thirty patients with stage IB-IVA AC/ASC were treated with whole pelvis external beam radiotherapy. A high-dose-rate intracavitary brachytherapy was delivered once per week at a fractional dose of 6 Gy. For TP-CCRT, the patients received cisplatin and paclitaxel.
RESULTS
A complete response was achieved in 17 patients (77.3%) in the TP-CCRT group and 4 patients (50.0%) in the P-CCRT group. The 5-year OS rate in the TP-CCRT and P-CCRT groups was 74.2% and 25.0% (p=0.0094), the central DFS rate was 58.0% and 12.5% (p=0.0267), and the distant DFS rate was 63.6% and 12.5% (p=0.0042), respectively.
CONCLUSION
TP-CCRT achieves a considerably better disease control for AC of the cervix, leading to a better OS.
背景/目的：我们回顾性分析了局部晚期宫颈癌（AC）/腺鳞癌（ASC）采用顺铂联合紫杉醇同期放化疗（TP-CCRT）的治疗效果。
患者和方法
30 例 IB-IVA 期 AC/ASC 患者接受全骨盆外照射放疗。高剂量率腔内近距离放疗每周一次，每次 6Gy。TP-CCRT 组患者接受顺铂和紫杉醇治疗。
结果
TP-CCRT 组完全缓解率为 77.3%（17/22），P-CCRT 组为 50.0%（2/4）。TP-CCRT 组和 P-CCRT 组的 5 年 OS 率分别为 74.2%和 25.0%（p=0.0094），中心无进展生存率分别为 58.0%和 12.5%（p=0.0267），远处无进展生存率分别为 63.6%和 12.5%（p=0.0042）。
结论
TP-CCRT 可显著改善宫颈癌 AC 的疾病控制，从而提高总生存率。
Zotero 插件